

Scott J Myers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5597021/publications.pdf>

Version: 2024-02-01

21
papers

4,237
citations

567281

15
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

6132
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Glutamate Receptor Ion Channels: Structure, Regulation, and Function. <i>Pharmacological Reviews</i> , 2010, 62, 405-496. | 16.0 | 2,973 |
| 2 | Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. <i>Nature Neuroscience</i> , 1999, 2, 867-872. | 14.8 | 360 |
| 3 | Human GRIN2B variants in neurodevelopmental disorders. <i>Journal of Pharmacological Sciences</i> , 2016, 132, 115-121. | 2.5 | 180 |
| 4 | Antidepressant-relevant concentrations of the ketamine metabolite (2 <i>R</i> ,6 <i>R</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 T Sciences of the United States of America, 2019, 116, 5160-5169. | 7.1 | 120 |
| 5 | GENETIC REGULATION OF GLUTAMATE RECEPTOR ION CHANNELS. <i>Annual Review of Pharmacology and Toxicology</i> , 1999, 39, 221-241. | 9.4 | 98 |
| 6 | Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. <i>F1000Research</i> , 2019, 8, 1940. | 1.6 | 92 |
| 7 | Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects. <i>Neuron</i> , 2015, 85, 1305-1318. | 8.1 | 57 |
| 8 | Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. <i>Brain</i> , 2020, 143, 2039-2057. | 7.6 | 51 |
| 9 | Heterogeneous clinical and functional features of GRIN2D-related developmental and epileptic encephalopathy. <i>Brain</i> , 2019, 142, 3009-3027. | 7.6 | 49 |
| 10 | De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases. <i>Human Mutation</i> , 2019, 40, 2393-2413. | 2.5 | 48 |
| 11 | A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons. <i>ACS Chemical Neuroscience</i> , 2018, 9, 306-319. | 3.5 | 42 |
| 12 | Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors. <i>Nature Communications</i> , 2019, 10, 321. | 12.8 | 32 |
| 13 | A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder. <i>Movement Disorders</i> , 2018, 33, 992-999. | 3.9 | 26 |
| 14 | Inhibition of Glutamate Receptor 2 Translation by a Polymorphic Repeat Sequence in the 5'-Untranslated Leaders. <i>Journal of Neuroscience</i> , 2004, 24, 3489-3499. | 3.6 | 25 |
| 15 | Hodgkin-Huxley-Katz Prize Lecture: Genetic and pharmacological control of glutamate receptor channel through a highly conserved gating motif. <i>Journal of Physiology</i> , 2020, 598, 3071-3083. | 2.9 | 23 |
| 16 | Negative allosteric modulation of GluN1/GluN3 NMDA receptors. <i>Neuropharmacology</i> , 2020, 176, 108117. | 4.1 | 17 |
| 17 | Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([¹⁸ F]N2B-0518) for GluN2B Subunit in the Brain. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2263-2275. | 3.5 | 13 |
| 18 | The GRIN3 c.2477G > A Variant Causes an Exaggerated Startle Reflex, Chorea, and Multifocal Myoclonus. <i>Movement Disorders</i> , 2020, 35, 1224-1232. | 3.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A GluN2B-selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, JPET-AR-2020-000370. | 2.5 | 7 |
| 20 | A de novo GRIN1 Variant Associated With Myoclonus and Developmental Delay: From Molecular Mechanism to Rescue Pharmacology. <i>Frontiers in Genetics</i> , 2021, 12, 694312. | 2.3 | 6 |
| 21 | Opportunities for Precision Treatment of <i>GRIN2A</i> and <i>GRIN2B</i> Gain-of-Function Variants in Triheteromeric N-Methyl-D-Aspartate Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 381, 54-66. | 2.5 | 5 |